HER2 Guidelines for Breast Cancer Could Misclassify Some Patients

The American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for HER2 gene amplification testing may leave some patients at risk for misclassification and inappropriate treatment according to a recent report from the Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California in Los Angeles.

 Cancer Network

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.